Belantamab mafodotin in multiple myeloma

References

• Abramson HN. Immunotherapy of multiple myeloma: promise and challenges. Immunotargets Ther. 2021 Sep 9;10:343–371. PMID: 34527606; PMCID: PMC8437262. DOI:10.2147/ITT.S306103
   PubMed Web of Science ®Google Scholar
• Leong S, Lam HPJ, Kirkham Z, et al. Antibody drug conjugates for the treatment of multiple myeloma. Am J Hematol. 2023 Mar;98(Suppl 2):S22–S34. Epub 2022 Oct 24. PMID: 36199262. DOI:10.1002/ajh.26750
   PubMedGoogle Scholar
• Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19(12):1641–1653.
   PubMed Web of Science ®Google Scholar
• Trudel S, Lendvai N, Popat R, et al. Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9(4):37.
   PubMed Web of Science ®Google Scholar
• Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–221. DOI:10.1016/S1470-2045(19)30788-0
   PubMed Web of Science ®Google Scholar
• Nooka AK, Cohen A, Lee HC. Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: final analysis of the DREAMM-2 Trial. Blood. 2022;140(Supplement 1):7301–7303. DOI:10.1182/blood-2022-164877
   Google Scholar
• Quach H, Gironella M, Lee C, et al. Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (Rrmm): dreamm-6 arm-a interim analysis. JCO. 2022;40(16_suppl):8017. DOI:10.1200/JCO.2022.40.16_suppl.8017
   Web of Science ®Google Scholar
• Trudel S, McCurdy A, Sutherland H, et al. Part 1 results of a dose-finding study of Belantamab Mafodotin in combination with Pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM). Blood. 2021;138(Supplement 1):1653. DOI:10.1182/blood-2021-147101
   PubMedGoogle Scholar
• Popat R, Nooka A, Stockerl-Goldstein K, et al. DREAMM-6: safety, tolerability and clinical activity of Belantamab Mafodotin (Belamaf) in combination with Bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):19–20. DOI:10.1182/blood-2020-139332
   Google Scholar
• Trudel S, Nooka A, Fecteau D, et al. 1105tiP - DREAMM 4: a phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM). Ann Oncol. 2019;30(v447):v447. DOI:10.1093/annonc/mdz251.039
   PubMedGoogle Scholar
• Nooka AK, Weisel K, van de Donk NW, et al. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: dreamm-5 study design. Future Oncol. 2021;17(16):1987–2003. DOI:10.2217/fon-2020-1269
   PubMed Web of Science ®Google Scholar
• Weisel K, Hopkins TG, Fecteau D, et al. Dreamm-3: a phase 3, open-label, randomized study to evaluate the efficacy and safety of Belantamab Mafodotin (GSK2857916) monotherapy compared with Pomalidomide plus low-dose dexamethasone (Pom/Dex) in participants with relapsed/refractory multiple myeloma (RRMM). Blood. 2019;134(Supplement_1):1900.
   Web of Science ®Google Scholar
• Rifkin RM, Boyd K, Grosicki S, et al. DREAMM-7: a phase III study of the efficacy and safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and dexamethasone (B-Vd) in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):53–54. DOI:10.1182/blood-2020-139181
   Web of Science ®Google Scholar
• Usmani SZ, Alonso Alonso A, Quach H, et al. DREAMM-9: phase I study of Belantamab Mafodotin plus standard of Care in Patients with transplant-ineligible newly diagnosed multiple myeloma. Blood. 2021;138(Supplement 1):2738. DOI:10.1182/blood-2021-153315
   Google Scholar
• Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma re-fractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019 Sep 1;33(9):2266–2275. DOI:10.1038/s41375-019-0435-7
   PubMed Web of Science ®Google Scholar
• Shragai T, Magen H, Lavi N, et al. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multicentre retrospective study. Br J Haematol. 2023 Jan;200(1):45–53.
   PubMed Web of Science ®Google Scholar
• Farooq AV, Degli Esposti S, Popat R, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody–drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020;9(4):889–911. DOI:10.1007/s40123-020-00280-8
   PubMed Web of Science ®Google Scholar
• Cohen AD, Lee HC, Trudel S, et al. Impact of prolonged dose delays on response with belantamab mafodotin (Belamaf; GSK2857916) treatment in the in the DREAMM-2 study: 13-month follow-up. Clin Lymphoma Myeloma Leuk. 2020;20(Suppl. 1):abstract MM 250. DOI:10.1016/S2152-2650(20)30949-6
   Google Scholar
• De Novellis D, Fontana R, Giudice V, et al. Innovative Anti-CD38 and Anti-BCMA targeted therapies in multiple myeloma: mechanisms of action and resistance. Int J Mol Sci. 2022 Dec 30;24(1):645. DOI:10.3390/ijms24010645
   PubMed Web of Science ®Google Scholar
• Weisel K, Krishnan A, Schecter JM. Matching- adjusted indirect treatment comparison to assess the comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and melphalan flufenamide-dexamethasone in HORIZON for the treatment of patients with triple-class exposed relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022 Sep;22(9):690–701.
   PubMed Web of Science ®Google Scholar